Effect of Tripotassium Dicitratobismuthate in Duodenal Ulcer Patients Refractory to Cimetidine

以Tripotassium Dicitratobismuthate 治療對Cimetidine頑抗這十二指腸潰瘍

伍偉華(Wai-Wah Ng) ； 黎國洪(Kwok-Hung Lai) ； 蔡養德(Yang-Te Tsai) ； 李壽東(Shou-Dong Lee) ； 賴啓賢(Chii-Shyan Lay) ； 譚振熀(Tseng-Nip Tam) ； 羅錦河(Gin-Ho Lo) ； 林勤益(Ching-Yih Lin)

《中華民國消化系醫學會雜誌》 4卷4期 (1987/12) Pp. 153-157

https://doi.org/10.6557/GJTa.198712_4(4).0001

摘要

臺北榮民總醫院胃腸科自民國74年7月至75年11月間在進行TDB對Cimetidine治療頑抗之十二指腸潰瘍患者研究，以了解其臨床應用之意義。本研究包括20例會經接受Cimetidine口服日量800毫克達8週或以上，經內視鏡診斷為不癒之十二指腸潰瘍患者，另一組為20例未曾接受抗潰瘍藥物治療者。兩組均無年齡、性別、生活習慣及潰瘍狀況上之差異，均接受TDB 300mg片劑每日口服4次治療，經4週與8週後，頑抗性潰瘍組的癒合率分別為65%及85%，初次治療組分別為25%及65%。本研究顯示兩組病患之4週癒合率以Cimetidine治療頑抗組為高，而兩組之8週癒合率未具統計意義。副作用以其氧化物所造成之黑色糞便及舌苔沉積為主。在年齡較大及併發慢性十二指腸潰瘍之患者，經傳統性胃酸抑制藥物無效者，本文建議採用TDB作第二線臨床用藥。

關鍵字

Tripotassium Dicitratobismuthate(TDB) ； 頑抗性十二指腸潰瘍 ； cimetidine

並列摘要

Twenty endoscopically proven duodenal ulcers patients who were refractory to cimetidine treatment, 800mg daily for 8 weeks, were changed to treatment with tripotassium dicitratobismuthate (TDB), 300mg four times daily. They were compared to twenty Patients with duodenal ulcers who were initially treated with TDB in the same regimen. Our results indicate that the healing rate of ulcers in the refractory group (65%) at4weeks was significantly superior to the initially treated group (25%) (P＜0.05), while the healing rate at8weeks was not statistically significant in both groups (85% us 65%). It is suggested that TDB, being a cytoprotective drug, is effective in the treatment of refractory duodenal ulcer.

並列關鍵字

tripotassium dicitratobismuthate(TDB) ； refractory duodenal ulcer ； cimetidine